Predictive Oncology Q2 net loss $3.2M on revenue $0.3M; enters biomarker discovery market

Axe Compute Inc.

Net loss of $3.2M ($0.68 per share) on revenue of $278,722, down 43% YoY from $490K.
Cash and equivalents $5.3M at June 30, 2024; raised $3.1M net from ATM and $1.3M post-quarter from warrants.
Entering biomarker discovery market after successful ovarian cancer study with UPMC; market estimated at $51.5B.
Cost savings initiative to cut cash used in operations by ~20% annually, consolidating Birmingham lab into Pittsburgh.
Gross margin fell to 45% from 67% due to higher labor costs and lower STREAMWAY system sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.